Teva Pharmaceutical Industries Limited (TLV:TEVA)
5,596.00
-49.00 (-0.87%)
Jul 9, 2025, 3:44 PM IDT
TLV:TEVA Revenue
Teva Pharmaceutical Industries had revenue of $3.89B USD in the quarter ending March 31, 2025, with 1.89% growth. This brings the company's revenue in the last twelve months to $16.62B, up 3.82% year-over-year. In the year 2024, Teva Pharmaceutical Industries had annual revenue of $16.54B with 4.40% growth.
Revenue (ttm)
$16.62B
Revenue Growth
+3.82%
P/S Ratio
1.03
Revenue / Employee
$465.62K
Employees
35,686
Market Cap
64.03B ILS
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16.54B | 698.00M | 4.40% |
Dec 31, 2023 | 15.85B | 921.00M | 6.17% |
Dec 31, 2022 | 14.93B | -953.00M | -6.00% |
Dec 31, 2021 | 15.88B | -781.00M | -4.69% |
Dec 31, 2020 | 16.66B | -228.00M | -1.35% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Danel (Adir Yeoshua) | 2.81B |
Kamada | 622.70M |
Bait Bakfar | 104.50M |
BrainsWay | 161.81M |
SofWave Medical | 235.09M |
Novolog (Pharm-Up 1966) | 2.07B |
Ilex Medical | 922.08M |
Epitomee Medical | 37.17M |
Teva Pharmaceutical Industries News
- 1 day ago - Teva Pharmaceutical Industries Ltd (TEVA) Recognized Among World's Most Sustainable Companies | ... - GuruFocus
- 12 days ago - Teva Releases Q2 2025 Aide Memoire - GlobeNewsWire
- 12 days ago - Viatris Eye Drops Data Shows Promise For Blurred Near Vision - Benzinga
- 13 days ago - Alvotech's Lenders Lower Interest on Senior Secured Term Loan Facility - Benzinga
- 13 days ago - Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025 - GlobeNewsWire
- 16 days ago - Final Data from Teva's PEARL Real-World Study Reinforce the Long-term Effectiveness of AJOVY® (fremanezumab) for the Prevention of Chronic and Episodic Migraine - GlobeNewsWire
- 23 days ago - Teva and Fosun partner to develop TEV-56278 against cancers - Seeking Alpha
- 23 days ago - Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology - PRNewsWire